A 42-year-old woman from Tamil Nadu with lepromatous leprosy has completed 12 months of WHO multidrug therapy (MDT) with rifampicin, dapsone, and clofazimine. Skin smear microscopy now shows no acid-fast bacilli. She reports persistent brownish-black discoloration of skin and conjunctivae that developed during treatment. She is concerned about the cosmetic appearance. What is the most appropriate next step?

Explanation

## Clinical Scenario Analysis The patient has: - Completed WHO MDT for lepromatous leprosy (12 months) - Achieved bacteriological cure (no AFB on skin smear) - Developed clofazimine-induced pigmentation as an adverse effect - Concerns about cosmetic appearance ## Clofazimine: Pharmacology and Adverse Effects ### Mechanism of Pigmentation **Key Point:** Clofazimine causes brown-black discoloration of skin, conjunctivae, and internal organs due to: - Lipophilic nature → accumulation in fatty tissues and sebaceous glands - Redox cycling and free radical generation → melanin deposition - Concentration in dermis and subcutaneous tissue ### Timeline and Reversibility | Aspect | Details | |--------|----------| | **Onset** | Usually after 4–6 weeks of therapy | | **Intensity** | Dose and duration dependent | | **Reversibility** | Gradual fading over 6–12 months after discontinuation | | **Complete clearance** | May take 1–2 years in some patients | | **Mechanism of fading** | Slow mobilization from fatty tissues and renal/biliary excretion | **High-Yield:** Clofazimine pigmentation is **NOT permanent** and is a cosmetic, not clinical, problem. It does not indicate organ toxicity and does not require intervention beyond stopping the drug. ### Management of Clofazimine-Induced Pigmentation 1. **Discontinue clofazimine** — once MDT is complete and bacteriological cure is achieved 2. **Reassure the patient** — pigmentation will gradually fade 3. **Counsel on timeline** — expect fading over 6–12 months; complete clearance may take up to 2 years 4. **Sun protection** — may help reduce visibility of discoloration 5. **No specific treatment** — vitamin C, depigmenting agents, or other medications do not accelerate fading **Clinical Pearl:** Clofazimine-induced discoloration is one of the most common reasons for poor adherence in leprosy treatment. Pretreatment counseling about this reversible effect is essential. ## Why Continuation or Alternative Therapy Is Not Indicated **Key Point:** After completion of WHO MDT with bacteriological cure: - Continuing clofazimine serves no therapeutic purpose - Prolonged exposure increases risk of other adverse effects (GI upset, ichthyosis, photosensitivity) - Minocycline is not a substitute for clofazimine in MDT and is not indicated for monotherapy in lepromatous leprosy **Mnemonic:** **STOP** — **S**top clofazimine (cure achieved), **T**ime for fading (6–12 months), **O**ther drugs not needed, **P**igmentation is reversible